This article covers 3.2.4 Psychological problems of the AQA GCSE Psychology specification.
Wiles (2013): Does Adding CBT Help Treatment-Resistant Depression?
- Wiles (2013) ran the CoBalT trial in UK primary care to test whether adding CBT to usual drug treatment helps people whose depression had not responded to medication alone.
- It matters because it provides effectiveness evidence for CBT under realistic NHS conditions.
- It uses a controlled comparison, which lets researchers judge whether CBT itself made the difference.
Key Idea
- If adding CBT improves outcomes over medication alone, it supports CBT as an effective add-on treatment.
- The design compares two groups, so any difference can be linked to the CBT.
Aim
- To test whether CBT added to usual care reduces depression more than usual care alone.
- To help people whose depression had not improved on antidepressants.
Method
- Sample: around 469 UK primary-care patients with treatment-resistant depression, who had taken antidepressants for at least six weeks without responding.
- Participants were randomly allocated to one of two groups, which reduces bias.
- One group received CBT plus their usual care, including medication; the control group continued with usual care only.
- Depression was measured at six months using a standard symptom questionnaire, and the groups were compared.
Example
- Randomly allocating patients means the two groups start off similar, so a later difference is more likely due to the CBT.
- The usual-care-only group acts as a control, showing what would have happened without the added therapy.
Findings
- At six months, about 46 per cent of the CBT group had responded, meaning at least a halving of symptoms, compared with about 22 per cent of the control group.
- The improvement in the CBT group was still evident at longer follow-up.
- Wiles concluded that adding CBT to usual care is an effective option for treatment-resistant depression.
Evaluation
- Controlled design: the randomised comparison with a control group means the difference in outcomes can be attributed to CBT rather than chance or the passage of time.
- Real-world relevance: the large UK primary-care sample means the results apply well to everyday NHS practice.
- Generalisability: because every participant had treatment-resistant depression, the findings may not generalise to people with milder depression or to those treated with CBT and no medication.
- Practical cost: CBT needs trained therapists and time, so it is costly to provide, and results depend on people staying in treatment rather than dropping out.
Common Mistake
- When you evaluate, tie the point to this sample: treatment-resistant patients are a specific group, which is stronger than a vague 'not generalisable' claim.
- Describe participants as patients receiving care, keeping the tone measured and respectful.
Linking the Study Back to Therapy
- Use Wiles to argue that CBT is effective, especially when combined with medication.
- Link it to how CBT works, changing thoughts and behaviour, from the therapy you studied.
- Balance it with its limits on cost and generalisability.
Self review
- What did Wiles (2013) investigate?
- How were the two groups treated?
- What was the main finding?
- Why might the treatment-resistant sample limit generalisation?